-transparent.png){kind=logo}
A live attenuated oral cholera vaccine has been given to volunteers with complete safety. The vaccine strain appeared to multiply significantly in intestinal contents and to result in appreciable vibriocidal antibody response. Subsequent challenge with virulent Inaba vibrios demonstrated substantial protection from clinical illness and from vibrio shedding. The possibility of reversion to toxin production is discussed.
Related Publications
W E Woodward, and
R H Gilman, and
R B Hornick, and
J P Libonati, and
R A Cash
June 1997,
Lancet (London, England),
W E Woodward, and
R H Gilman, and
R B Hornick, and
J P Libonati, and
R A Cash
July 1997,
The Journal of infectious diseases,
W E Woodward, and
R H Gilman, and
R B Hornick, and
J P Libonati, and
R A Cash
March 1971,
Nature,
W E Woodward, and
R H Gilman, and
R B Hornick, and
J P Libonati, and
R A Cash
February 2021,
Proceedings of the National Academy of Sciences of the United States of America,
W E Woodward, and
R H Gilman, and
R B Hornick, and
J P Libonati, and
R A Cash
June 2016,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
W E Woodward, and
R H Gilman, and
R B Hornick, and
J P Libonati, and
R A Cash
April 1969,
Bulletin of the World Health Organization,
W E Woodward, and
R H Gilman, and
R B Hornick, and
J P Libonati, and
R A Cash
October 2010,
BMC biology,
W E Woodward, and
R H Gilman, and
R B Hornick, and
J P Libonati, and
R A Cash
June 1997,
Infection and immunity,
W E Woodward, and
R H Gilman, and
R B Hornick, and
J P Libonati, and
R A Cash
January 2020,
Human vaccines & immunotherapeutics,
W E Woodward, and
R H Gilman, and
R B Hornick, and
J P Libonati, and
R A Cash
December 2021,
Vaccines,
